Drugs / KHK2375
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02623751 | Nov 2015 → Oct 2020 | breast cancer | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Kyowa Kirin, Inc. | Kyowa Kirin Announces Discontinuation for Developing KHK2375 (Entinostat) kyowakirin.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KHK2375 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02623751 ↗ |
| Route | Oral | “KHK2375 will be orally administered once weekly.” NCT02623751 ↗ |